| 臺大學術典藏 |
2021-09-01T01:54:00Z |
The emerging epidemic of estrogen-related cancers in young women in a developing Asian country
|
Lin C.-H.; Chen Y.-C.; Chiang C.-J.; Lu Y.-S.; Kuo K.-T.; Huang C.-S.; Cheng W.-F.; Lai M.-S.; You S.-L.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:00Z |
Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas
|
Kuo S.-H.; Yeh K.-H.; Wu M.-S.; Lin C.-W.; Hsu P.-N.; Wang H.-P.; Chen L.-T.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:01Z |
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
|
Hsu C.; Yang T.-S.; Huo T.-I.; Hsieh R.-K.; Yu C.-W.; Hwang W.-S.; Hsieh T.-Y.; Huang W.-T.; Chao Y.; Meng R.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:01Z |
The impact of diabetes mellitus on prognosis of early breast cancer in Asia
|
Chen W.-W.; Shao Y.-Y.; Shau W.-Y.; Lin Z.-Z.; Lu Y.-S.; Chen H.-M.; Kuo R.N.C.; ANN-LII CHENG; Lai M.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:01Z |
Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A
|
Huang C.-Y.; Wei C.-C.; Chen K.-C.; Chen H.-J.; ANN-LII CHENG; Chen K.-F. |
| 臺大學術典藏 |
2021-09-01T01:54:01Z |
A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: A novel approach by using meta-regression
|
Shen Y.-C.; Hsu C.; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:02Z |
Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer
|
Kuo W.-H.; Lin P.-H.; Huang A.-C.; Chien Y.-H.; Liu T.-P.; Lu Y.-S.; Bai L.-Y.; Sargeant A.M.; Lin C.-H.; ANN-LII CHENG; Hsieh F.-J.; Hwu W.-L.; Chang K.-J. |
| 臺大學術典藏 |
2021-09-01T01:54:02Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:02Z |
Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3
|
Chen K.-F.; Chen H.-L.; Liu C.-Y.; Tai W.-T.; Ichikawa K.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:03Z |
Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma
|
Yen C.-H.; Lu Y.-C.; Li C.-H.; Lee C.-M.; Chen C.-Y.; Cheng M.-Y.; Huang S.-F.; Chen K.-F.; ANN-LII CHENG; Liao L.-Y.; Lee Y.-H.W.; Chen Y.-M.A. |
| 臺大學術典藏 |
2021-09-01T01:54:03Z |
Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma
|
Yang S.-H.; Lin L.-W.; Fang Y.-J.; ANN-LII CHENG; Kuo S.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:03Z |
Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma
|
ANN-LII CHENG; Shen Y.-C.; Zhu A.X. |
| 臺大學術典藏 |
2021-09-01T01:54:03Z |
Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3
|
Tai W.-T.; ANN-LII CHENG; Shiau C.-W.; Liu C.-Y.; Ko C.-H.; Lin M.-W.; Chen P.-J.; Chen K.-F. |
| 臺大學術典藏 |
2021-09-01T01:54:04Z |
Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells
|
Lin Y.-C.; Wu M.-H.; Wei T.-T.; Chung S.-H.; Chen K.-F.; ANN-LII CHENG; Chen C.-C. |
| 臺大學術典藏 |
2021-09-01T01:54:04Z |
Antiangiogenic strategies for the treatment of hepatocellular carcinoma
|
Hsu C.; Shen Y.-C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:04Z |
Asian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia
|
Han K.-H.; Kudo M.; Ye S.-L.; Choi J.Y.; Poon R.T.-P.; Seong J.; Park J.-W.; Ichida T.; Chung J.W.; Chow P.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:04Z |
T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement
|
Kuo S.-H.; ANN-LII CHENG; Lin C.-W.; Hsu C.-H.; Wu M.-S.; Yeh K.-H.; Tzeng Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-09-01T01:54:05Z |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study
|
Ch'Ang H.-J.; Lin Y.-L.; Wang H.-P.; Chiu Y.-F.; Chang M.-C.; Hsu C.-H.; Tien Y.-W.; Chen J.-S.; Hsieh R.-K.; Lin P.-W.; Shan Y.-S.; ANN-LII CHENG; Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T. |
| 臺大學術典藏 |
2021-09-01T01:54:05Z |
Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era
|
Chen I.C.; Lin C.H.; Huang C.S.; Lien H.C.; Hsu C.; Kuo W.H.; Lu Y.S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:05Z |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials
|
Yang S.-H.; Kuo Y.-H.; Tien Y.-W.; Hsu C.; Hsu C.-H.; Kuo S.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:06Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:06Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Hsu C.-Y.; Shen Y.-C.; Yu C.-W.; Hsu C.; Hu F.-C.; Hsu C.-H.; Chen B.-B.; Wei S.-Y.; ANN-LII CHENG; Shih T.T.-F. |
| 臺大學術典藏 |
2021-09-01T01:54:06Z |
Establishment of a novel MALT lymphoma cell line, ma-1, from a patient with t(14;18)(q32;q21)-positive Helicobacter Pylori-independent gastric MALT lymphoma
|
Kuo S.-H.; Weng W.-H.; Chen Z.-H.; Hsu P.-N.; Wu M.-S.; Lin C.-W.; Jeng H.-J.; Yeh K.-H.; Tsai H.-J.; Chen L.-T.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:07Z |
Prognostic molecular markers in Women aged 35 years or younger with breast cancer: Is there a difference from the older patients?
|
Lin C.-H.; Lu Y.-S.; Huang C.-S.; Kuo K.-T.; Wang C.-C.; You S.-L.; Lin P.-H.; Chang D.-Y.; Kuo W.-H.; Chang K.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:07Z |
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
|
Harmon C.S.; DePrimo S.E.; Raymond E.; ANN-LII CHENG; Boucher E.; Douillard J.-Y.; Lim H.Y.; Kim J.S.; Lechuga M.J.; Lanzalone S.; Lin X.; Faivre S. |
